Endocrine Research Updates

For Medical Professionals

GLP-1RAs offer excellent benefits for cardiovascular diabetes.
A new meta-analysis affirms improvements in cardiovascular, kidney and overall outcomes in patients given a GLP-1RA versus SGLT2i for management of type 2 diabetes. Even in those without established cardiovascular disease, significant benefits are achieved with glucagon-like peptide-1 receptor agonists.
Testosterone levels increase risk of nonalcoholic fatty liver disease.
Findings from a nonobese population study advance the role of androgens as a driver of abdominal adiposity, leading to greater risk of nonalcoholic fatty liver disease.
Diabetic gastroparesis affects one-third of those with long-term diabetes.
A new surgical procedure, a promising minimally invasive, endoscopic device, and new uses for established drugs offer relief from gastrointestinal symptoms of this common complication of diabetes.
When prescribing a psych med, patients should be referred for weight loss.
Regardless of the type of psychiatric medications taken, including antidepressants and antipsychotics, patients who enroll in a weight loss program achieve weight loss, similar to those not taking these medications. This is important progress for many individuals who fear weight gain when they take psychopharmacological medications.
Thyroid hormones play a significant role in onset of NAFLD.
Type 2 diabetes is not the only precursor to nonalcoholic fatty liver disease, patients with thyroid disease also appear at elevated risk.
Hypoparathyroidism is the last endocrine disorder treated with hormone therapy.
The standard of care for hypoparathyroidism has been calcium and vitamin D replacement, making it the last endocrine deficiency for which hormone replacement is the treatment of choice.
The poor prognosis for aggressive thyroid tumors may improve with new drugs.
Considerable progress in understanding the molecular basis of rare thyroid cancer cases has led to the introduction of new drugs that target specific genetic mutations, enabling personalized care and improved survival.
Patients need are met for greater flexibility in diabetes drug formulations.
FDA approvals lead to the introduction of new formulations of glucagon, insulin, and statin therapy for patients with diabetes and cardiovascular disease, fulfilling a precept of precision medicine.
Increased comorbidity of migraines with metabolic and endocrine diseases.
Considering the increased likelihood that patients with migraine may also have hypothyroidism, diabetes, metabolic syndrome, and obesity, elevates the prospect of better overall medical management and improved quality of life.
Cardiac events present a greater risk of death than a diagnosis of cancer.
As people survive longer with cancer, including thyroid and other endocrine-related types, they face the added risk of cardiovascular disease morbidity and mortality, requiring ongoing clinical vigilance.
Need to focus on prevention to reduce risks of heart disease and diabetes.
Clinical Practice Guidance refocuses attention to visceral fat vs BMI, and lipid fractions beyond LDL, among other key risk factors. Also, even older patients need to continue statin therapy to avoid cardiac events.
Gentle nudges offer doctors a better approach to encourage weight loss.
Researchers focus on seven healthy eating strategies available to clinicians to make your next discussion about body weight to be more productive and constructive, drawn from results of a meta-analysis.
Central hypothyroidism needs treatment with levothyroxine.
A combination of mifepristone and levothyroxine proves beneficial in controlling excess cortisol in patients with central hypothyroidism.
NAFLD is a common complication of poorly controlled type 2 diabetes.
Patients who attend structured weight loss programs appear most successful at reverseing NAFLD but cost and lack of insurance reimbursement remain prohibitive obstacles.
Dose and potency of diabetes drugs affected by microbiome status.
Harvard scientists report an integral role of gut bacteria acting as a gateway to bioavailability of levodopa in patients with Parkinson's disease; their work echoes similar research finding the microbiome also affects efficacy of diabetes drugs.
Primary care practitioners must gain comfort with transgender patients
Need to infuse more sensitivity in meeting the medical needs of transgender patients while assuring comfort in the delivery of necessary medical care.
Benefits of statins override any secondary concerns in reducing heart disease.
Despite concerns about the possible adverse effects that statins may in reducing levels of already low sex hormones, most people with type 2 diabetes are at risk for cardiovascular disease and so have more to gain from cholesterol-lowering therapy.
A 7-question survey helps clinicians tailor treatment for hypothyroidism.
In patients with Hashimoto’s thyroiditis, adjusting for levothyroxine dose and formulation should be informed by EMPATHY trial findings to attain TSH range and achieve optimal patient compliance.
Applying the 2019 Obesity Guide will achieve better weight controls for patients
Despite our failed efforts historically, the myriad tools from pharmacotherapy to devices and gastric procedures now available should prompt renewed focus on individualizing care to improve morbidity and mortality, aided by the 2019 Obesity Algorithm.
The Spatz adjustable intragastric balloon helps break through a weight plateau.
Obesity remains a fundamental clinical challenge to be aided by a range of new weight loss devices that promise to meet the varying needs of individual patients as spotlighted at Digestive Disease Week.
close X